Clinical trials: Unfractionated Heparin
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Healthy
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and…
- Trial name
- NCT02206087
- Testing
- PER977, Heparin Sodium
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Coronary Artery Disease
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery…
- Trial name
- REVERSAL-PCI (NCT00715455)
- Testing
- REG1, Unfractionated Heparin
- Where
- 6 sites in United States, Argentina
- Volunteers
- 26 people
- Sponsor
- Regado Biosciences, Inc.
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Healthy
Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers
This trial holds minimal risk to the trial volunteers and consists of obtaining whole blood via venipuncture to perform coagulation parameter measurements to define a Normal Reference Range.
- Trial name
- NCT06261580
- Testing
- TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen
- Where
- 3 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Venous Thromboembolism
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism.
- Trial name
- NCT01803022
- Where
- France
- Volunteers
- 419 people
- Sponsor
- LEO Pharma
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT).
- Trial name
- NCT05785819
- Testing
- VLX-1005
- Where
- 14 sites in United States
- Volunteers
- 24 people
- Sponsor
- Veralox Therapeutics
Chronic Obstructive Pulmonary Disease
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
- Trial name
- COPD (NCT00457951)
- Testing
- Open-Label, ODSH
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 158 people
- Sponsor
- Jazz Pharmaceuticals
Anticoagulant
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
Pharmacodynamic Study - Phase I Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/mL; Blau Farmacêutica S/A.
- Trial name
- NCT05788900
- Testing
- Heparin
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Blau Farmaceutica S.A.
Heparin-induced Thrombocytopenia Type II
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral…
- Trial name
- NCT00861692
- Testing
- argatroban
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Tanabe Pharma Corporation
Healthy Subjects
A Study in Healthy Subjects to Assess the Safety and Tolerability of a 120-hour Continuous Infusion of M6229
This is a Phase I, single-center, randomized, single-blind, placebo-controlled study in healthy subjects assessing the safety, tolerability and pharmacokinetic profile of three different dose levels of M6229 when administered…
- Trial name
- NCT07285603
- Testing
- M6229
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Matisse Pharmaceuticals
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Angioplasty, Transluminal, Percutaneous Coronary
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
The purpose of this study is to compare the safety and effectiveness of abciximab, an anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary intervention when administered in combination with two…
- Trial name
- NCT00269880
- Testing
- Heparin, Abciximab
- Volunteers
- 2,792 people
- Sponsor
- Centocor, Inc.
Thrombosis
Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
The objective of this trial is to demonstrate the clinical utility of fixed-dose SC Desirudin for the prophylaxis of thrombosis as an alternative to heparin-based anticoagulation.
- Trial name
- DESIR-ABLE (NCT00913133)
- Testing
- Desirudin
- Where
- 16 sites in United States
- Volunteers
- 516 people
- Sponsor
- Canyon Pharmaceuticals, Inc.
Acute Coronary Syndrome
Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)
A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner.
- Trial name
- NCT00251576
- Testing
- A-Phase: tirofiban; Z-Phase simvastatin, Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years, Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
- Volunteers
- 4,497 people
- Sponsor
- Organon and Co
Heparin
Study With Heparin Sodium in Subcutaneous Administration
The purpose of this phase I study is to know the pharmacodynamic profile in humans of the sodium heparin of porcine origin of the company União Química, building from the pharmacodynamic data generated its pharmacokinetic…
- Trial name
- NCT03113084
- Testing
- Sodium Heparin UQ subcutaneous drug administration, Sodium Heparin FK subcutaneous drug administration
- Where
- Brazil
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- União Química Farmacêutica Nacional S/A
Chronic Renal Failure
Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.
The Heparin form a complex with a plasma protein, antithrombin III (ATIII), which is an endogenous anticoagulant. This complex inhibits the formation of thrombin and accelerates its destruction.
- Trial name
- Heparin (NCT01229072)
- Testing
- Heparin sodic, heparin liquemine
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Trial name
- SAFE (NCT00358735)
- Testing
- ActiveCare CECT device, Enoxaparin
- Where
- 9 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Chronic Kidney Diseases, Patient Requiring Heparin Free Dialysis Treatments
Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
This study will assess the safety and efficacy of heparin free hemodialysis (HD) performed with dialyzers with Endexo in adult end-stage renal disease (ESRD) subjects on thrice-weekly in-center HD.
- Trial name
- NCT04511338
- Testing
- Dialyzer with Endexo
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fresenius Medical Care North America
Blood Loss, Surgical, Coagulation Disorder
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
The goal of this clinical trial is to learn if reltodecacog alfa (VMX-C001) works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that…
- Trial name
- EQUILIBRIX-S (NCT07288489)
- Testing
- Reltodecacog alfa, Usual Pharmacological Care
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 800 people
- Sponsor
- VarmX B.V.